African Congress On Sickle Cell Disease invites Dr Pradeep Mahajan to conduct a session in Nigeria

The conference is expected to provide a platform for knowledge exchange, sharing of experiences of best practices and informed recommendations on Sickle Cell management, control and policies

African Congress, Sickle Cell Disease, Pradeep Mahajan, Nigeria, Pradeep Mahajan, StemRx Bioscience Solutions, Nigeria, ACSCD, Power of the collective voice

The Ministry of Health in Nigeria, has invited Dr Pradeep Mahajan,  Chairman, and MD, StemRx Bioscience Solutions to conduct a  session on ‘Mesenchymal Cell-based Therapy: An alternative to joint replacement in sickle cell anaemia patients with avascular necrosis,’ on November 2. The Congress represents a unique and ideal platform for the International sickle cell community to meet, discuss, share, learn and connect in order to find solutions to reduce the impact of sickle cell on communities in Africa and around the world, and the theme for the Congress is ‘Overcoming Sickle Cell Disease - Power of the collective voice’.

Sickle cell disease (SCD) is one of the world’s most common genetic diseases, affecting an increasing number of people. It poses a significant public health problem, notably in sub-Sahara Africa, the Middle East, parts of India, the Caribbean, and Brazil. It is at this time, it is the need of the hour to come together as a collective to seek best practices and innovation to address the challenges of sickle cell disease. With an aim to tackle sickle cell disease, the 1st African Congress on Sickle Cell Disease (ACSCD) will be held in Nigeria. The conference is expected to provide a platform for knowledge exchange, sharing of experiences of best practices and informed recommendations on Sickle Cell management, control, and policies.

Dr Pradeep Mahajan, Chairman, and MD, StemRx Bioscience Solutions, highlighted, “It is the need of the hour to spread awareness regarding sickle cell disease. The conference will provide a platform for knowledge exchange, sharing of our experiences of best practices and informed recommendations on Sickle Cell management, control, and policies. I will be conducting a session on ‘Mesenchymal Cell-based Therapy: An alternative to joint replacement in sickle cell anaemia patients with avascular necrosis’. I am glad and honored to be a part of this educational event wherein world-renowned sickle cell and public health experts, caregivers, will collectively voice towards sickle cell disease prevention.”

Share